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Abstract
Enhanced expression and activity of the Na+/H+ exchanger isoform 1 (NHE1) has been im-
plicated in cardiomyocyte hypertrophy in various experimental models. The upregulation of
NHE1 was correlated with an increase in osteopontin (OPN) expression in models of cardi-
ac hypertrophy (CH), and the mechanism for this remains to be delineated. To determine
whether the expression of active NHE1-induces OPN and contributes to the hypertrophic
response in vitro, cardiomyocytes were infected with the active form of the NHE1 adenovi-
rus or transfected with OPN silencing RNA (siRNA-OPN) and characterized for cardiomyo-
cyte hypertrophy. Expression of NHE1 in cardiomyocytes resulted in a significant increase
in cardiomyocyte hypertrophy markers: cell surface area, protein content, ANP mRNA and
expression of phosphorylated-GATA4. NHE1 activity was also significantly increased in
cardiomyocytes expressing active NHE1. Interestingly, transfection of cardiomyocytes with
siRNA-OPN significantly abolished the NHE1-induced cardiomyocyte hypertrophy. siRNA-
OPN also significantly reduced the activity of NHE1 in cardiomyocytes expressing NHE1
(68.5±0.24%; P<0.05), confirming the role of OPN in the NHE1-induced hypertrophic re-
sponse. The hypertrophic response facilitated by NHE1-induced OPN occurred indepen-
dent of the extracellular-signal-regulated kinases and Akt, but required p90-ribosomal S6
kinase (RSK). The ability of OPN to facilitate the NHE1-induced hypertrophic response
identifies OPN as a potential therapeutic target to reverse the hypertrophic effect induced
by the expression of active NHE1.
Introduction
Cardiovascular diseases (CVDs) are one of the leading causes of death worldwide despite the
advances in treatment [1]. Cardiac hypertrophy (CH) is a condition characterized by the en-
largement of cardiomyocytes following chronic and acute morbidities [2]. CH that is left
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unresolved results in left ventricular dysfunction and heart failure [3]. Previous reports have
suggested that increased activity of the Na+/H+ exchanger (NHE) isoform 1, a cardiac specific
isoform of the NHE exchanger family, is involved in CH [4,5,6] and ischemia/reperfusion (I/R)
injury [7]. NHE1 is a ubiquitously expressed housekeeping glycoprotein that maintains intra-
cellular pH through exchange of one intracellular H+ for one extracellular Na+ [8,9]. The impli-
cation of NHE1 in CH has been highlighted in guanylyl cyclase-A knockout (GC-A KO) mice,
which demonstrated CH and enhanced NHE1 activity [10]. In addition, complimentary genet-
ic evidence for the key role of NHE1 in CH has been demonstrated in transgenic mice express-
ing a cardiac specific active form of NHE1, rather than a wild type form of NHE1, had an
exacerbated hypertrophic response [11]. Furthermore, pharmacological inhibition of NHE1 ac-
tivity was sufficient to reduce isoproterenol-induced CH [12,13]. The encouraging evidence
has led to clinical trials in which an NHE1 inhibitor was used in patients with myocardial in-
farctions. These studies demonstrated severe cerebrovascular side effects leading to enhanced
mortality [14]. Despite the complications associated with the administration of NHE1 inhibi-
tors, delineating the molecular mechanisms downstream of NHE1 activation in the setting of
CH is necessary to develop specific strategies to indirectly inhibit NHE1.
Recent studies involving transgenic mice expressing active NHE1 [5] and mineralocorti-
coid/salt-induced cardiac fibrosis in rats [15] were associated with the activation of NHE1 and
osteopontin (OPN) protein and mRNA expression. Moreover, Sgk1-induced CH and upregu-
lation of NHE1 were correlated with an increase in OPN expression [6,16]. OPN, a matricellu-
lar protein involved in mediating inflammation and contributing to the pathogenesis of CH
[17–19], is increased under conditions of hypoxia [20] and following stimulation with endothe-
lin, norepinephrine, angiotensin II and aldosterone [21,22], conditions in which NHE1 also ap-
pears to be active. In addition, inhibition of NHE1 was correlated with a significant reduction
in OPN expression [6,15]. These findings suggest a molecular link between enhanced NHE1
activity and OPN, a pathway that has never been clearly defined.
OPN has been suggested to function through the calcineurin/nuclear factor activated T cells
(CaN/NFAT) pathway [23,24] and GATA4 [17]. The CaN/NFAT pathway has also been impli-
cated in NHE1 induced CH [25,26]. Osteopontin [17,27] and NHE1 [28–30] have also been
shown to activate the mitogen activated protein kinases (MAPK) and phosphatidylinositide-3-
kinases (PI3K) in a cell-specific manner. Therefore, OPN appears to be a key regulator of similar
hypertrophic signaling pathways activated during NHE1-induced cardiomyocyte hypertrophy.
Our study was undertaken to delineate the cellular mechanism by which NHE1 induces
OPN and its contribution to the NHE1-mediated hypertrophic response. We demonstrated for
the first time that increased NHE1 activity stimulated OPN, which induced an amplification
loop promoting CH associated with altered NHE1 activity.
Materials and Methods
Materials. All routine chemicals were purchased from BD Biosciences (San Jose, CA), Fisher Sci-
entific (Ottawa, ON) or Sigma (St. Louis, MO). EMD87580 was a generous gift of Dr. N. Beier
of Merck KGaA (Frankfurt, Germany). RSK inhibitor (BI-D1870) was obtained from the Uni-
versity of Dundee (Scotland, United Kingdom). Primary antibodies used for western blotting in-
cluding mouse monoclonal anti-HA-tag (#2376, 6E2), rabbit polyclonal anti-extracellular signal
regulated kinase (ERK)1/2 (#9102), mouse monoclonal phospho-ERK1/2 (Thr202/Tyr204)
(#9106), rabbit polyclonal protein kinase B (Akt) (#9272), rabbit polyclonal phospho-Akt
(Ser473) (#9271) and phospho-p90RSK (Ser380) (#9341) were purchased from Cell Signaling
Technology (Pickering, ON); mouse monoclonal anti-NHE1 was from BD Biosciences Phar-
mingen (San Diego, CA), rabbit polyclonal anti-RSK 1 (C-21) (sc-231) and RSK 2 (C-19)
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(sc-1430), goat polyclonal GATA4 (C-20) (sc-1237) and rabbit polyclonal phospho-GATA4
(Ser262) (sc-32823) were from Santa Cruz Biotechnology (Santa Cruz, CA); rabbit polyclonal
anti-OPN (ab8448), α-tubulin (ab4074) and glyceraldehyde-3-phosphate dehydrogenase
GAPDH (ab9485) antibodies were from Abcam (Cambridge, MA). Secondary polyclonal anti-
bodies including goat-anti-mouse, goat-anti-rabbit and donkey-anti-goat, conjugated to horse-
radish peroxidase were purchased from Jackson ImmunoResearch (West Grove, PA) or Abcam.
Adenoviral preparation. The pAdTrack plasmid was used to engineer the OPN and NHE1
containing adenoviruses as previously described [9,11]. Both the human NHE1 (PYN4+) (a gen-
erous gift from Dr. Larry Fliegel, University of Alberta, Edmonton, Alberta) [11] and mouse
OPN (BC057858) (a generous gift from Dr. Alain Gadeau, INSERM, Pessac, France) [18] plas-
mids contained the hemagglutinin (HA) tag and green fluorescent protein (GFP). The NHE1
plasmid also contained mutations in the Lys641, Arg643, Arg645 and Arg647 sites (to glutamic
acid) that render the protein constitutively active [11].
Isolation and culture of neonatal rat ventricular cardiomyocytes. All experimental proce-
dures involving neonatal rats were in accordance with guidelines set out by the Canadian
Council on Animal Care and carried out in Edmonton, Alberta, Canada and the Institutional
Animal Care and Use Committee at Qatar University, Doha, Qatar. The Institutional Animal
Care and Use Committee at Qatar University, Doha, Qatar has specifically approved this proj-
ect (Research Ethics Approval Number: QU-IACUC 007/2012). Ethical approval was received
from the University of Alberta, Edmonton, Alberta, Canada. Cardiomyocytes from 1–3 day-
old neonatal rat pups were isolated as described previously [31]. Briefly, hearts were extracted
and the isolated ventricles were digested using (2%) DNase (w/v), (0.5%) collagenase (w/v),
and (2%) trypsin (w/v). The digested tissue was centrifuged at 800 rpm for 1 minute at 37°C in
isolating media (DMEM/F12 1:1 media, 20% fetal bovine serum (FBS), 1% penicillin/strepto-
mycin, and 50 μg/mL gentamycin mixed stock solution). The pellet was resuspended in plating
media (DMEM/F12, 11% horse serum, 5% FBS, 1% penicillin/streptomycin, and 50 μg/mL
gentamycin mixed stock solution) and incubated at 37°C for 2 hours. The cell suspension was
centrifuged at 1,000 rpm for 2 minutes at 37°C and the remaining pellet was resuspended in
plating media. Cardiomyocytes were plated on Primaria-coated dishes (Falcon) at a density of
2.0 × 106 cells/well. NRVMs were cultured for 48 hours at 37°C in a humidified atmosphere
(95% O2-5% CO2) prior to infection with the respective adenoviruses.
Differentiation and culturing of H9c2 cardiomyocytes. H9c2 myoblasts are a clonal cell line
derived from the embryonic BD1X rat heart tissue and were obtained from European Collec-
tions of Cell Cultures. They have been reported to display comparable hypertrophy-associated
traits to primary cultures of cardiomyocytes when stimulated with hypertrophic agents [32].
H9c2 myoblasts were initially cultured in DMEM/F12 1:1 culture media supplemented with
10% FBS and 1% penicillin/streptomycin at 37°C in a humidified atmosphere (95% O2-5%
CO2) [33]. H9c2 myoblasts were differentiated into the cardiac phenotype by culturing in
DMEM/F12 1:1 supplemented with 1% horse serum, 1% penicillin/streptomycin and 0.1μM
all-trans-retinoic acid over a five day period [34]. Following differentiation, H9c2 cardiomyo-
cytes were cultured in DMEM/F12 1:1 culture media supplemented with 1% FBS and devoid of
antibiotics for 24 hours prior to infection with the adenoviruses and/or transfection with
siRNA OPN.
Adenoviral infection or siRNA transfection of cardiomyocytes. Cardiomyocytes were in-
fected for 24 hours with active NHE1 expressing adenovirus, the OPN adenovirus or an ade-
novirus containing GFP using a multiplicity of infection (MOI) of 10, 20 or 30 as indicated.
Lipofectamine 2000 (Invitrogen) was used to transfect cardiomyocytes with 100 nM siRNA
OPN (siRNA OPN-1 5’-GAUGAUAGGUAUCUGAAAUTT-3’ and siRNA OPN-2: 5’-
CGGAUGACUUUAAGCAAGATT-3’) or 30 nM universal scrambled siRNA (Eurogentec,
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http://www.eurogentec.com) for 24 hours according to the manufacturer’s instructions. Car-
diomyocytes co-transfected with the active form of the NHE1 adenovirus and siRNA were
transfected with siRNA-OPN 4 hours post infection with the active form of the NHE1 adeno-
virus. Cardiomyocytes infected/transfected with the respective adenovirus in the presence and
absence of siRNA were maintained at 37°C in a humidified atmosphere (95% O2-5% CO2) for
24 hours prior to cell lysis and other assays.
Phenylephrine and BI-D1870 treatment of cardiomyocytes. H9c2 cells were treated with ei-
ther vehicle or 100 μM phenylephrine (PE) for 30 minutes in the presence and absence of
10 μM BI-D1870. Treated cardiomyocytes were maintained at 37°C in a humidified atmo-
sphere (95% O2-5% CO2) for 24 hours prior to cell lysis.
Western blot analysis. Cardiomyocytes were lysed 24 hours post-infection and/or siRNA
OPN transfection using radio-immunoprecipitation protein assay (RIPA) buffer as described
earlier [11]. Cell lysates were centrifuged at 14,000 rpm at 4°C and the supernatant containing
the proteins were collected. The total amount of protein present in each sample was quantified
using the DC protein assay kit according to the manufacturer’s instructions. For determination
of protein expression by western blotting, up to 40 μg of protein was resolved on 10% SDS-PAGE
and transferred on to nitrocellulose membranes. NHE1 and OPN protein expression were nor-
malized to GAPDH or α-tubulin. Phosphorylated GATA4 protein expression was normalized to
total protein expression. For the p-ERK/ERK, p-RSK/RSK and p-Akt/Akt the phosphorylated ki-
nase expression were normalized to the respective kinase total protein expression. Cells were son-
icated in 1 mL of MAPK cell lysis buffer (mM (50 Na-pyrophosphate, 50 NaF, 50 NaCl, 5 EDTA,
EGTA, 0.1 sodium orthovandate, 10 Hepes pH 7.4, 0.5 PMSF), 0.1% Triton X-100, 10 mg/mL
leupeptin) [35]. All primary antibodies were incubated in a dilution of 1:1000–2000, while sec-
ondary antibodies were diluted at 1:5000. Immunoreactive proteins were visualized using en-
hanced chemiluminescence (Amersham Biosciences) and imaged and quantified using the
Alpha Innotech FluorChem Imager (R&D Systems).
Measurement of NHE1 activity. Cardiomyocytes plated on coverslips were loaded with 3 μg/
mL pH sensitive dye 2,7-bis(carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester (BCEC-
F-AM). The change in H+ concentration was measured using a PTI Deltascan spectrofluorome-
ter (Photon Technology International; London, Ontario). The excitation wavelengths were set
at 502.5 nm and 440 nm and the emission wavelength was set at 528.7 nm [36]. The coverslip
was initially maintained in a pre-warmed solution of Na+-normal buffer (mM (135 NaCl, 5 KCl,
1.8 CaCl2, 1 MgSO4, 5.5 Glucose, 10 HEPES) at 37°C and was then pulsed with 50 mM ammoni-
um chloride to induce an acid load [36]. Following acidification, the coverslip was placed in
Na+-normal buffer to allow the cardiomyocytes to recover. Each coverslip was equilibrated in a
three-step pH calibration buffer solution containing 135 mMN-methyl-glucamine and KCl,
10 μMnigericin and adjusted to a pH of 8, 7 or 6. The three-step pH calibration was used to gen-
erate a standard curve in which the fluorescence output measurements were converted into in-
tracellular pH [16]. The initial rate of recovery following an induced acid load was measured
and used as an indicator of the NHE1 activity.
Measurement of cell surface area. The average surface area of 50–70 randomly selected in-
fected/transfected cardiomyocytes was measured out of 3–4 experiments. The cardiomyocytes
were visualized with an inverted microscope equipped with a monochrome digitalized camera
using 20X magnification. The surface area was determined using the AxioVision Imaging Soft-
ware (Carl Zeiss Microimaging, New York, NY).
Measurement of protein content. Protein content was measured as described previously
[37]. Briefly, infected/transfected cardiomyocytes were washed twice in 1 x PBS and collected
by trypsinization. The total number of cardiomyocytes was calculate using a Countess1 Cell
Counting Chamber Slide (Invitrogen). Protein concentration of infected/transfected
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cardiomyocytes lysed in RIPA buffer was measured using the DC protein assay kit (Biorad).
Protein content was determined by dividing the total amount of protein (μg) by the total num-
ber of cardiomyocytes.
Expression of ANP and OPNmRNA using Reverse Transcription-Polymerase Chain Reac-
tion. RNA was extracted from cardiomyocytes using the Total RNA Purification Kit (Norgen).
Total RNA (1 μg) was reverse transcribed into cDNA using SuperScript1 III First Strand Synthe-
sis SuperMix (Invitrogen). 100 ng of cDNA was amplified using sense 50-CTGCTAGACCACCT
GGAGGA-30, antisense 50-AAGCTGTTGCAGCCTAGTCC-30 and sense 5’-CAGTCGATGTC
CCTGACGG-3’, antisense 5’-GTTGCTGTCCTGATCAGAGG-3’ ANP and OPN primer se-
quences, respectively, using a 2x PCRMaster Mix (Norgen) [38,39]. β-actin cDNA was primed
with sense 50-ACGCAGCTCAGTAACAGTCC-30 and antisense 50-AGATCAAGATCATTGCTC
CTCCT-30 primer sequence and used to normalize mRNA expression. Following an initial dena-
turation of 3 minutes at 95°C, the samples were denatured at 95°C for 30 seconds, annealed at
60°C for 30 seconds and extended at 72°C for 1 minute for 35 cycles. A final extension of 72°C
for 5 minutes was performed in order to ensure the maximum recovery of products. ANP, OPN
and β-actin were quantified using the Alpha Innotech FluorChem Imager. The changes in ANP
and OPNmRNA levels were normalized to β-actin and then to control.
Statistics. All values expressed were compared to control or NHE1 infected cardiomyocytes ±
SEM (%). Student’s t test was used to compute differences between groups where a P<0.05 was
considered a significant difference.
Results
Activation of NHE1 stimulates OPN expression
Previous reports have demonstrated a simultaneous upregulation of NHE1 and OPN in models
of CH [5,6,15,16]. In order to determine whether NHE1 activation induces OPN expression
during cardiomyocyte hypertrophy, H9c2 cardiomyocytes and NRVMs were infected with ade-
noviral vectors coding a constitutively active NHE1 for 24 hours. An enhanced green fluores-
cent protein (GFP)-expressing adenovirus under the control of the same promoter of the
NHE1 and OPN adenoviruses served as a control. Our results indicated that infection of H9c2
cardiomyocytes or NRVMs with the NHE1 adenovirus successfully overexpressed the HA-
tagged protein (S1A Fig and S2A Fig), as well as total NHE1 protein expression (S1B Fig and
S2B Fig), an effect that was not observed in cardiomyocytes infected with the GFP adenovirus
alone. OPN protein and mRNA expression were then examined in cardiomyocytes infected
with the active form of the NHE1 adenovirsu. OPN protein expression was examined in
NRVMs 24 hours post infection. Our results revealed that expression of the OPN protein, ap-
pearing as a doublet at 66 kDa [17,40], was significantly elevated in cardiomyocytes expressing
the active form of the NHE1 adenovirus (342.7%±69.22% vs. 100.0±33.93% control; P<0.05
(Fig 1A). OPN mRNA expression was significantly increased in cardiomyocytes expressing ac-
tive NHE1 in H9c2 cardiomyocytes (296.3%±53.60% vs. 100.0% control; P<0.05) (Fig 1B). To
identify the role of OPN in the NHE1 mediated hypertrophic effect we induced NHE1 activity
in cardiomyocytes and blocked the OPN using siRNA (S3B Fig). The remaining portion of our
study in which OPN was blocked using siRNA was carried out in H9c2 cardiomyocytes. The
H9c2 cell model has been suggested to be a more suitable host for siRNA transfection as it rep-
resents a form of immortal mammalian cell line as opposed to NRVMs, which may require
electroporation to allow for the uptake of siRNA [41]. Inhibition of OPN with siRNA directed
against OPN reduced the NHE1-induced upregulation of OPN protein expression by more
than 50% in H9c2 cardiomyocytes at the 24 hour time point (49.5±9.18% vs. 100.0% NHE1;
P< 0.05) (Fig 1C and S3A Fig). Our results demonstrated for the first time that the
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Fig 1. Upregulation of NHE1 in cardiomyocytes enhances OPN expression. A: Upper panel, representative western blot of OPN protein expression in
cell lysates of NRVMs infected with GFP (control) or active NHE1 adenovirus for 24 hours. Immunoblotting was against OPN (doublet at 66 kDa) and GAPDH
(38 kDa). Lower level, quantification of relative levels of totalOPN protein expression (n = 4; representative of 2–3 preparations). B: Upper panel,
representative DNA gel of OPNmRNA expression in H9c2 cardiomyocytes infected with GFP (control) or active NHE1 adenovirus for 24 hours using an MOI
of 20 and 30, respectively. cDNA amplification was against OPN (206 bp) and β-actin (174 bp). Lower level, quantification of OPNmRNA expression in H9c2
cardiomyocytes normalized to β-actin (n = 6–7; representative of 4 experiments). Results expressed as % of control (GFP) ±%SEM. *p < 0.05 vs. control. C:
Upper panel, representative western blot of OPN protein expression of H9c2 cardiomyocytes infected with NHE1 adenovirus (30 MOI) in the presence and
absence of 100nM siRNAOPN for 24 hours. Immunoblotting was against OPN (doublet at 66 kDa) and α-tubulin (50 kDa); lower panel, quantification of
relative levels of OPN protein expression (n = 6–9; representative of 2–3 experiments). Results are expressed as % of NHE1 ±%SEM. *p < 0.05 vs. NHE1 +
siRNA.
doi:10.1371/journal.pone.0123318.g001
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upregulation of active NHE1 in cardiomyocytes induced the expression of OPN in both
NRVMs and H9c2 cardiomyocytes.
OPN is critical for NHE1-induced cardiomyocyte hypertrophy
Although OPN has been suggested to mediate CH [17–19], whether OPN contributes to cardi-
omyocyte hypertrophy induced by elevated expression and activity of NHE1 has not been
shown. In vitro, cardiomyocytes infected with the OPN adenovirus alone (expressing a three
fold increase in OPN mRNA vs. control) did not cause a significant increase in cell surface area
(153.2±26.65% of control), protein content (156.5±19.86% of control) or ANP mRNA (141.5
±86.65% of control). Transfection of cardiomyocytes with siRNA-OPN alone (in the absence
of the NHE1 adenovirus) was also unable to reverse any parameters of cardiomyocyte hyper-
trophy compared to control (cell surface area (51.9±1170.77% of control), protein content
(96.8±17.81% of control) or ANP mRNA (66.3±0.59% of control)). However, cardiomyocytes
expressing the active form of NHE1 adenovirus induced cardiomyocyte hypertrophy as indi-
cated by the significant increase in cell area in both the H9c2 cardiomyocytes and NRVMs
(Fig 2A and 2B). Total protein content (Fig 2D) and ANP mRNA expression (Fig 2E) were also
significantly increased (136.8±11% and 247.7±30.81% of control; P<0.05 respectively) in H9c2
cardiomyocytes expressing the active form of the NHE1 adenovirus. The downregulation of
OPN by transfection of siRNA directed against OPN in cardiomyocytes expressing active
NHE1 fully reversed the NHE1 hypertrophic effect as indicated by the significant reduction in
cell surface area (68.5±0.24% vs. 190.9±8.66%; P< 0.05), total protein content (87.8±12.58% vs.
136.8±11%, P< 0.05) and ANP mRNA expression (64.6±19.9% vs. 247.7±30.81% P< 0.05)
(Fig 2B–2E). Transfection of H9c2 cardiomyocytes with scrambled siRNA did not alter protein
content (121.3±27.48% of control). Our findings reveal for the first time that NHE1-induced
OPN expression contributed to the hypertrophic response in cardiomyocytes and that partial
inhibition of OPN prevented the NHE1 induced hypertrophic response.
The NHE1-mediated hypertrophic effect has previously been demonstrated to be driven at
least in part by the CaN/NFAT pathway [25,26]. We tested whether OPN contributes to this
pathway by examining the level of GATA4 phosphorylation, a key activator of the CaN/NFAT
pathway that leads to the expression of hypertrophic genes. Active NHE1 enhanced phosphor-
ylation of GATA4 (144.0±14.01% of control; P<0.05) (Fig 3). GATA4 phosphorylation was
significantly reduced following inhibition of OPN by transfection of cardiomyocytes with
siRNA compared to cardiomyocytes expressing active NHE1 (93.7±6.31% vs. 144.0±14.01%
NHE1; P< 0.05). Our findings revealed for the first time that NHE1 induced OPN expression
regulated hypertrophic gene transcription.
OPN regulates NHE1 activity
To ascertain the involvement of OPN on enhancing/maintaining NHE1 activity, NHE1 activity
was measured in cardiomyocytes expressing active NHE1 in the presence and absence of OPN
siRNA (Fig 4). NHE1 activity in cardiomyocytes infected with active NHE1 was significantly
increased compared to control (586.5±103.54% of control; P<0.05). NHE1 activity was re-
duced by more than 75% by downregulating OPN expression in cardiomyocytes (235.0
±92.14% vs. 586.5±103.54% NHE1; P< 0.05). These data demonstrated that the expression of
OPN in cardiomyocytes contributed to NHE1 activity suggesting that OPN played a role in en-
hancing/maintaining NHE1 activity.
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RSK facilitates the NHE1 induced OPN expression
Several kinases including ERK 1/2, RSK and Akt have been shown to be induced during condi-
tions of CH [42]. Whether NHE1 induced OPN expression in cardiomyocytes is mediated in
part by the MAPK signaling pathway has not been demonstrated. To further understand how ac-
tive NHE1 increases OPN expression in cardiomyocytes, we measured the expression of the
Fig 2. OPN contributes to NHE1-induced cardiomyocyte-hypertrophy. A: upper panel, representative fluorescence microscopy images of NRVMs
infected with GFP (control) or active NHE1 adenovirus 24 hours post infection; lower panel, cell surface area of at least 50–70 infected NRVMs from 4–6
individual dishes were measured to represent 3–4 experiments, results expressed as % of control (GFP) ±%SEM. B: Upper panel, representative
fluorescence microscopy images of H9c2 cardiomyocytes infected with adenoviruses containing GFP (control) or active NHE1 in the presence and absence
of siRNA OPN for 24 hours; lower panel, cell surface area of at least 50–70 H9c2 cardiomyocytes from 4–6 individual dishes were measured to represent 3–4
experiments. C: Protein content of H9c2 cardiomyocytes expressed as μg/10 x 106 cell. D: Quantification of ANPmRNA expression in H9c2 cardiomyocytes
normalized to β-actin (n = 6–7; representative of 4 experiments). Results are expressed as % of control (GFP) ±%SEM. *p < 0.05 vs. control, # vs. NHE1.
doi:10.1371/journal.pone.0123318.g002
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phosphorylated and total proteins of ERK 1/2 (S4 Fig), Akt (S4 Fig) and RSK (Fig 5A) following
24 hours of infection with the active NHE1 adenovirus. The ratio of phosphorylated to total ERK
1/2 and Akt were not significantly different in cardiomyocytes expressing active NHE1 (S4 Fig).
Similarly, cardiomyocytes infected with the active form of the NHE1 adenovirus demonstrated a
trend towards increase in the ratio of phosphorylated to total RSK (138.2±43.02% of control),
but not a significant increase. Further studies were carried out to delineate the effects of RSK in
the NHE1-induced OPN hypertrophic response following a time dependent stimulation with
PE, a known NHE1 stimulator [43], in the presence of BI-D1870 (Fig 5B). Our findings revealed
that PE induced the expression of OPN following 30 minutes of PE stimulation, an effect that
was significantly reduced in the presence of BI-D1870 (53.7±10.45% vs. of control; P< 0.05).
These results suggested that the NHE1 induced OPN expression may in part be dependent
on RSK.
Discussion
The expression of constitutively active NHE1 and OPN have both been shown to individually
contribute to the development and progression of CH [5,15]. Recently, the upregulation of
Fig 3. OPN siRNA regresses expression of the GATA-4 hypertrophic transcription factor.Upper panel,
representative western blot of relative amounts of phosphorylated and total GATA4 expression in H9c2
cardiomyocytes infected with GFP (control) or active NHE1 in the presence and absence of siRNAOPN.
Lower panel: quantification of experiments measuring the ratio of phosphorylated to total GATA4 protein.
Results are expressed as% of control (GFP) ±%SEM (n = 4–7; representative of 3–5 experiments). *p < 0.05
vs. control, # vs. NHE1.
doi:10.1371/journal.pone.0123318.g003
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NHE1 in CH models was correlated with an increase in OPN expression. However, no reports
have directly investigated whether the expression of active NHE1 induces OPN and how OPN
contributes to the NHE1 mediated hypertrophic response in cardiomyocytes. This study dem-
onstrates demonstrated that OPN mRNA and protein expression are significantly increased in
cardiomyocytes expressing active NHE1, which in part maybe attributed to RSK.
In our study, H9c2 the myoblast cell line, derived from embryonic BD1X rat heart tissue
[44] in their differentiated form as cardiomyocytes [34] was used to block OPN expression in-
duced by infection with the active form of the NHE1 adenovirus. H9c2 cells have been shown
to display hypertrophy-associated traits comparable to primary cultures of cardiomyocytes
when stimulated with α1-adrenergic receptor agonists as well as high glucose treatment
[32,33]. As such, we chose to investigate the effects of downregulating OPN on NHE1-induced
cardiomyocyte hypertrophy in H9c2 cardiomyoblasts. In order to develop a more representa-
tive model, H9c2 cardiomyoblasts were differentiated into the cardiac phenotype using retinoic
acid. [34]. Retinoic acid has been shown to stimulate the expression of cardiac specific L-type
voltage-dependent Ca2+ channels (VDCCs), the cardiac sarcomeric heavy chain and myosin
light chains, which are parameters specific to the cardiac muscles cells [34,45,46]. Our choice
of H9c2 cardiomyocytes seemed more suited for our experiments with siRNA, since they repre-
sent a form of immortal mammalian cell line, which are easier to transfect [41] as oppose to
Fig 4. Downregulating OPN reduces NHE1-induced cardiomyocyte-hypertrophy and NHE1 activity.Cardiomyocytes plated on coverslips were
incubated with BCECF-AM and induced with an acid load using 50 mMNH4Cl. The rate of recovery following the acid induction was measured and used as
an indicator of NHE1 activity. Upper panel, representative traces of NHE1 activity assay in H9c2 cardiomyocytes infected with GFP (control) or NHE1 in the
presence and absence of siRNA OPN for 24 hours; lower panel, quantification of NHE1 activity (10–14 coverslips, from 3–4 experiments). Results are
expressed as % of control (GFP) ±%SEM. *p < 0.05 vs. control, # vs. NHE1.
doi:10.1371/journal.pone.0123318.g004
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NRVMs [31]. Moreover, we anticipated that siRNA OPN would be more effective at downre-
gulating the expression of OPN in H9c2 cardiomyocytes since they originate from myoblasts
[47,48].
OPN is differentially expressed as two isoforms, a secreted full length OPN (sOPN) and an
intracellular (iOPN) form [49]. sOPN, a matricellular protein of the extracellular matrix, binds
to the cell surface proteoglycans [50]. A large portion of the sOPN remains associated with the
surface of the extracellular matrix making it rather difficult to detect changes in the media
[51,52]. As a result, in the majority of in vitro studies [39,51–53] and in our study, OPN expres-
sion was examined in the cell lysates, where we demonstrated an increase in OPN mRNA and
protein expression, in agreement with previous findings [54] [55,56]. The increase in OPN ex-
pression appeared to occur in both NRVMs and H9c2 cardiomyocytes.
Cardiomyocytes expressing the active form of the NHE1 adenovirus significantly increased
cell surface area, protein content and ANP mRNA (Fig 2A–2D), confirming previous reports,
which have demonstrated that active NHE1 induces cardiomyocyte hypertrophy [11,26,30].
Cell area was measured in both H9c2 cardiomyocytes and NRVMs following infection with the
NHE1 adenovirus and in both models, a significant increase in cell area was observed. For the
first time our group demonstrated that the NHE1-mediated increase of cell surface area,
Fig 5. OPN contributes to NHE1-induced cardiomyocyte-hypertrophy through RSK. A. Upper panel: Representative western blot of relative amounts of
phosphorylated and total expression of RSK in NRVMs infected with GFP (control) or active NHE1. Immunoblotting was against phosphorylated and total
RSK (80–90 kDa) and normalized to GAPDH (38 kDa); lower panel, quantification of experiments measuring the ratio of phosphorylated to total protein for
RSK. Results are expressed as % of control (GFP) ±%SEM (n = 4; representative of 2 preparations). B. H9c2 cardiomyoblasts were treated with PE and/or
BI-D1870 (10 μM) for 24 h. Cells were lysed and equal amounts of protein were analyzed by SDS-PAGE/immunoblot Immunoblotting was against OPN
(doublet at 66 kDa) and α-tubulin (50 kDa); lower panel, quantification of relative levels of OPN protein expression (n = 4–5; representative of 5 experiments).
Results are expressed as % of control ±%SEM. *p < 0.05 vs. control.
doi:10.1371/journal.pone.0123318.g005
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protein content and ANP mRNA were significantly reduced upon down regulation of OPN.
Furthermore, our findings indicated that the upregulation of OPN alone in cardiomyocytes in-
fected with the OPN adenovirus was not sufficient to induce cardiomyocyte hypertrophy.
Taken together, our results suggest that OPN is permissive for the hypertrophic effects of active
NHE1 in cardiomyocytes, although it is not sufficient to induce cardiomyocyte hypertrophy
without NHE1.
Mraiche et al. demonstrated that transgenic mice expressing wild type NHE1 induced lower
expression of OPN and the hypertrophic response compared to transgenic mice expressing ac-
tivated NHE1 [5]. This highlighted the importance of active NHE1 in OPN induction. Interest-
ingly, overexpression of OPN alone in cardiomyocytes was not sufficient to significantly
induce a cardiomyocyte hypertrophy phenotype, further supporting the importance of the ex-
pression of active NHE1 in inducing the upregulation of OPN in cardiomyocyte hypertrophy.
The importance of NHE1 in inducing OPN has also been observed in conditions of metasta-
sis; where the activity of the αvβ3 integrin, an osteopontin receptor whose activity is regulated
by NHE1, was elevated thus allowing cell activation by OPN [57,58]. mRNA expression of
CD44, a receptor that also interacts with and causes the activation of OPN, was also shown to
be significantly elevated in transgenic mice expressing active NHE1 and exhibiting an upregu-
lation of OPN [59].
The expression of OPN has previously been shown to be upregulated in response to the acti-
vation of the CaN/NFAT pathway [60], which coincides with the enhanced nuclear transloca-
tion of the GATA4 transcription factor [17,23]. In our study, enhanced expression and activity
of NHE1 caused the exacerbation of cardiomyocyte hypertrophy, which is associated with the
activation of GATA4. This is in agreement with previous studies, which have shown that the ac-
tivation of NHE1 and cardiomyocyte hypertrophy were associated with activation of the CaN/
NFAT and GATA4 signaling [25,61]. In our study, we demonstrated for the first time that
NHE1 induced OPNmediated the phosphorylation of GATA-4, which is reflected by the de-
creased expression of the phosphorylated form of GATA4 in H9c2 cardiomyocytes co-infected
with the active form of the NHE1 adenovirus and siRNA-OPN. However, the direct role of the
CaN/NFAT pathway in the NHE1 induced OPN hypertrophic response remains unknown.
In the myocardium, RSK is considered a primary regulator of NHE1 activity through phos-
phorylation of the Ser703 site along the C-terminal, thereby facilitating the binding of the 14-3-3
protein to the phosphorylated Ser703 residue [62]. In cardiac tissue from SGK1+/+ mice, the phos-
phorylation of NHE1, as indicated by NHE1 immunoprecipitated samples using an anti-phos-
pho- (Ser) 14-3-3 antibody, was significantly higher compared to KOmice following
dexamethasone stimulation [63]. Several other kinases including ERK 1/2, Akt have been shown
to regulate NHE1 activity [8,28,29] as well as OPN expression in the setting of cardiomyocyte hy-
pertrophy [27,64]. Our findings suggest, as indicated by the ratio of phosphorylated to total
forms of the respective kinase protein expression, that following 24 hours of infection of cardio-
myocytes with NHE1, no significant changes in ERK½, Akt or RSK expression was observed
(S4 Fig and Fig 5A). This may in part be due to the timing of our experiments, which were car-
ried out 24 hours post-transfection with the NHE1 adenovirus. Our findings may also be attrib-
uted to the lower number of NRVM preparations used in this set of experiments. Nakamura
et al. demonstrated that the hypertrophic effects induced by enhanced activity of NHE1 occurred
independent of Akt activation, which is in agreement with our findings [30]. In addition, a recent
study has shown that CU-NP, a non-vasodilating natriuretic peptide, was able to inhibit and re-
verse NHE1-induced cardiomyocyte hypertrophy independent of ERK 1/2 pathway [65]. Our
findings also appear to be consistent with previous reports that have suggested a link between
NHE1 and RSK in mediating the hypertrophic response [28,29]. Interestingly, previous reports
have also identified an association between RSK and OPN. Inhibition of RSK in vitro has been
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previously associated with a downregulation in OPN expression [21]. In fact, RSK-induced acti-
vation of OPN-CD44 receptor in epithelial cells has been shown to be modulated upon activation
of the MEK and RSK pathways, all of which were decreased in the presence of FMK, a RSK in-
hibitor [66]. In our study, the inhibition of RSK through BI-D1870 reduced the NHE1-induced
OPN expression following PE (30 minutes) stimulation (Fig 5B) suggesting that the NHE1-in-
duced OPN upregulation may in part be mediated through RSK. However, further studies are re-
quired to elucidate the role of RSK in the NHE1 induced OPN hypertrophic cascade.
In this study, we demonstrate that OPN is able to facilitate the NHE1-induced hypertro-
phic response using an in vitromodel. Several studies have documented the importance of
OPN in the induction of both CH [17] and dilated cardiomyopathy [18] in vivo. Further stud-
ies will be necessary to examine the role of NHE1-induced OPN in a model in which cardio-
myocytes and fibroblasts are co-cultured. It will also be necessary to determine the cellular
interplay between OPN and NHE1 in an in vivo model of cardiac hypertrophy. Overall our
data demonstrates that the enhanced expression and activity of NHE1 causes an upregulation
of OPN, which in turn contributes to the hypertrophic response elicited in cardiomyocytes.
Interestingly, downregulation of OPN successfully reverted the hypertrophic response and de-
creased NHE1 activity.
Supporting Information
S1 Fig. Multiplicity of infection (MOI) of NHE1 adenoviral infection in NRVMs. Immuno-
blotting was against anti-HA tag for exogenous NHE1 (90–110 kDa), total NHE1 (90–110
kDa) or GAPDH (38 kDa). A: Representative western blot of NRVMs infected with control
(GFP) or active NHE1 adenovirus at an MOI of 10, 20 or 30, respectively for 24 hours and
probed against the anti-HA tag antibody (n = 3). B: Representative western blot of NRVMs in-
fected with control (GFP) or active NHE1 adenovirus at an MOI of 10, 20 or 30, respectively
for 24 hours and probed against the anti-NHE1 antibody (n = 3).
(TIF)
S2 Fig. MOI of NHE1 adenoviral infection in H9c2 cardiomyocytes. Immunoblotting was
against anti-HA tag for exogenous NHE1 (90–110 kDa), total NHE1 (90–110 kDa) or GAPDH
(38 kDa) protein expression. A: Representative western blot of H9c2 cardiomyocytes infected
with control (GFP adenovirus) using an MOI of 20 or 30 or NHE1 adenovirus using an MOI
of 10, 20 or 30, respectively for 24 hours and probed against the anti-HA tag antibody (n = 3).
B: Representative western blot of H9c2 cardiomyocytes infected with control (GFP) using an
MOI of 20 or 30 or active NHE1 adenovirus using an MOI of 10, 20 or 30 for 24 hours and
probed against the anti-NHE1 antibody (n = 3).
(TIF)
S3 Fig. OPN protein expression is greatest at 24 hours compared to 6 and 12 hours in H9c2
cardiomyocytes. A: OPN protein expression in H9c2 cardiomyocytes at 2, 6, 12 and 24 hours
after collecting cell lysates. Immunoblotting was against anti- OPN for total OPN (doublet at
66 kDa) and α- tubulin (50 kDa) (n = 3). B: Representative western blot of total OPN protein
expression of H9c2 cardiomyocytes infected with GFP 20 MOI, OPN 30 MOI, 30 nM universal
scrambled siRNA or 100 nM siRNA OPN for 24 hours. Immunoblotting was against anti-
OPN for total OPN (doublet at 66 kDa) and α- tubulin (50 kDa) (n = 3).
(TIF)
S4 Fig. ERK 1/2 and Akt are not implicated in NHE1-induced OPN expression and cardio-
myocyte-hypertrophy. Representative western blot of relative amounts of phosphorylated and
total protein expression of Akt and ERK 1/2 in NRVMs infected with GFP (control) or active
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NHE1. Immunoblotting was against phosphorylated and total Akt (60 kDa) or ERK 1/2 (43–44
kDa) and normalized to GAPDH (38 kDa).
(TIF)
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